Three-month DAPT in high bleeding risk patients receiving the SYNERGY stent was noninferior to a 12-month historical control for death or MI (5.6% vs 5.7%; P=0.0016 for noninferiority).
Cohort (n=2,009)
Yes
Effect estimate: difference -0.12% (95% CI 97.5% upper bound 1.63%)
Absolute Event Rate: 5.6% vs 5.7%
p-value: p=0.0016
Background: Prolonged dual antiplatelet therapy (DAPT) after percutaneous coronary intervention is associated with increased bleeding, despite a reduced incidence of ischemic events. The SYNERGY everolimus-eluting stent is a thin-strut platinum-chromium stent that elutes everolimus from a thin abluminal layer of bioabsorbable polymer. These design elements may facilitate rapid endothelialization and enable shorter-duration DAPT. Methods: EVOLVE Short DAPT prospectively evaluated the safety of 3-month DAPT in high bleeding risk patients treated with the SYNERGY everolimus-eluting stent, enrolling 2009 patients at 110 global sites. Patients with acute myocardial infarction or complex lesions were excluded. After percutaneous coronary intervention, patients were required to take DAPT (aspirin+P2Y 12 inhibitor) for 3 months, except those on chronic anticoagulation in whom aspirin was optional. Patients free of events (stroke, myocardial infarction, revascularization, and stent thrombosis) who discontinued P2Y 12 inhibitor at 3 months, but continued aspirin, and had at least 1 year of follow-up or an end point event were included in the primary analysis. Two powered coprimary end points were (1) death/myocardial infarction compared with a historical control and (2) study stent-related definite/probable stent thrombosis compared to a performance goal. Results: The analysis population consisted of 1487 patients. The adjusted rate of death/myocardial infarction between 3 and 15 months was 5.6% among patients receiving 3-month DAPT versus 5.7% patients in the 12-month DAPT control (propensity adjusted difference=−0.12%; 97.5% upper bound=1.63% which was less than the prespecified margin of 2.52; P non-inferiority =0.0016). The rate of study stent-related stent thrombosis between 3-15 months was 0.2% in the 3-month DAPT group (97.5% upper bound=0.63%; P =0.0005 for comparison to 1% performance goal). Conclusions: Favorable rates of ischemic outcomes were observed among selected high bleeding risk patients undergoing percutaneous coronary intervention with the SYNERGY everolimus-eluting stent who tolerated 3 months of P2Y 12 inhibitor and then discontinued it, supporting the safety of abbreviated DAPT with this stent platform. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02605447.
Kirtane et al. (Mon,) conducted a cohort in High bleeding risk after percutaneous coronary intervention (n=2,009). 3-month dual antiplatelet therapy (DAPT) vs. 12-month DAPT historical control was evaluated on Death or myocardial infarction between 3 and 15 months (difference -0.12%, 95% CI 97.5% upper bound 1.63%, p=0.0016). Three-month DAPT in high bleeding risk patients receiving the SYNERGY stent was noninferior to a 12-month historical control for death or MI (5.6% vs 5.7%; P=0.0016 for noninferiority).